Program
CEB-01
A development code. Also written as “CEB-01 membrane loaded with SN-38”.
Its studies are mostly in Pancreatic Neoplasms · Sarcoma, led by CEBIOTEX.
Furthest: phase 2, since May 15, 20253 company-led studies, 2 open or runningNext primary completion: Sep 2028 (early phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CEBIOTEX | 32 open or running | phase 2since May 15, 2025 | Oct 30, 2020 | Sep 2028early phase 1 · NCT06538857 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 30, 2020First study: phase 1 study in SarcomaFirst studyNCT04619056 · 21 enrolled · Spain
- Aug 1, 2024Early phase 1 study in Pancreatic NeoplasmsNCT06538857 · 39 enrolled · Spain
- May 15, 2025Phase 2 study in Locally Resectable Pediatrics TumorsNCT06986811 · 80 enrolled · Spain
Ahead
- Sep 2028Primary completion: early phase 1 study in Pancreatic NeoplasmsNCT06538857
- May 2029Primary completion: phase 2 study in Locally Resectable Pediatrics TumorsNCT06986811
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06986811Locally Resectable Pediatrics Tumors · Spain | 2 | Active, not recruiting | May 2029 | 80 |
| NCT06538857Pancreatic Neoplasms · Spain | Early 1 | Active, not recruiting | Sep 2028 | 39 |
| NCT04619056Sarcoma · Spain | 1 | Completed | Nov 28, 2025 | 21 |
How it is read
Names in the registry
- “CEB-01”, 2 entries
- “CEB-01 membrane loaded with SN-38”, 1 entry
Codes read as this program: CEB01.
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
- Sarcoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.